261 related articles for article (PubMed ID: 27817821)
1. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
Tashkin DP; Bateman ED; Jones P; Zubek VB; Metzdorf N; Liu D; Leonard T; Clerisme-Beaty E; Wise RA
Respir Med; 2016 Nov; 120():91-100. PubMed ID: 27817821
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
6. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
7. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
9. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
11. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
12. Effects of baseline symptom burden on treatment response in COPD.
Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
17. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
20. Bronchodilator Effect of Tiotropium via Respimat
Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]